Timo Minssen

In this intriguing discussion, Daniel Carpenter, a Harvard government expert on FDA regulations, Timo Minssen, a Copenhagen law professor specializing in biomedical innovation, and Chad Atalla from Microsoft Research explore the complexities of AI in pharmaceuticals and medical devices. They delve into the evolving FDA landscape, the critical balance between innovation and safety in drug approvals, and the innovative strategies needed for efficient clinical trials. The group highlights the importance of aligning AI technologies with societal values and overcoming bias in AI systems.